Ovarian CancerNCT07915336
Peer Ambassador in Gyn Onc Trials
A study testing Mentee encounters in people with Ovarian Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
The goal of this study is to learn if peer ambassador support will increase clinical trial enrollment in patients with ovarian cancer. Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer
- What is being tested?
- Mentee encounters
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 125 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Oct 2026to 30 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Mentees Inclusion Criteria:
- any patient with ovarian cancer who has never participated in a clinical trial
Ambassadors Inclusion Criteria:
- any patient who has participated in an interventional clinical trial
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
Official title: Peer Ambassador in Gynecologic Oncology Clinical Trials
The goal of this study is to learn if peer ambassador support will increase clinical trial enrollment in patients with ovarian cancer.
Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. The patient ambassador will be a patient with history of cancer who has participated in a clinical trial and can serve as an ambassador to facilitate discussions regarding education and awareness of clinical trials.
Read the detailed description
Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. The patient ambassador will be a patient with history of cancer who has participated in a clinical trial and can serve as an ambassador to facilitate discussions regarding education and awareness of clinical trials. This discussion will potentially assist mentees to make informed decisions about their engagement in discussing clinical trials, looking for clinical trials, and desire and acceptance of clinical trials. This will also allow ambassadors to gain information about perceived barriers regarding clinical trials.
This study will be a multi-institutional prospective cohort study conducted at Penn and Hopkins. We seek to identify approximately 10 patient ambassadors, who will be trained to lead 1:1 discussion with patient mentees. Each ambassador will be paired with up to 10 mentees. Each ambassador-mentee pairing will have 1-2 encounters (meetings) over the course of 12 months.
- Conditions
- Ovarian Cancer
- Being tested
- Mentee encounters
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mentee encountersOther
Mentee meetings as previously described
| Study group | Role | What they receive |
|---|---|---|
| Peer Ambassador Encounter | Experimental | Mentees will participate in an enrollment session, discussion session with an ambassador, close out session, and 12 month clinical care follow up during which electronic medical records will be reviewed to assess whether mentees are subsequently screened or enrolled in clinical trials. Receives: Other: Mentee encounters |
What is being measured
The primary outcome is the main question the study is designed to answer.
Attitude about enrolling in trials
Participants' attitudes about enrolling in trials will be assessed through the Attitudes Toward Cancer Trials Scales (ACTS). Scores will range from 18-126. The difference between pre and post intervention scores will be assessed.
Measured: 12 months from enrollment
Intent to Enroll in Trials
Participants' intent to enroll in trials will be assessed through a previously validated Attitudes and Intention to Enroll in Therapeutic Clinical Trials (AIET) instrument. Responses will range from yes or no.
Measured: 12 months from enrollment
Secondary outcomes (4)
Mentee knowledge regarding clinical trials before and after discussion sessions
This will be assessed using a knowledge of clinical trials questionnaire. Scores will range from 0-12. The difference between pre and post intervention scores will be assessed.
Measured: Within 12 weeks of completing all sessions
Feasibility of this ambassador program
Feasibility of this ambassador program will be assessed using the Feasibility of Intervention Measure (FIM). Scores will range from 1-5.
Measured: 12 months from study start
Acceptability of this ambassador program
Acceptability will be assessed using the Acceptability of Intervention Measure (AIM). Scores will range from 1-5.
Measured: 12 months from study start
Proportion of mentees in this program who enrolled onto a clinical trial
Mentees will be followed for 12 months and it will be documented if they enroll in a clinical trial. The percent of mentees who enroll in a clinical trial will be calculated.
Measured: 12 months from study start
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Johns Hopkins University
- Responsible party
- Principal investigator, Emily Ko, MD, Abramson Cancer Center at Penn Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07915336
- Sponsor's protocol ID
- UPCC 20826
- Other IDs
- IRB 26-7627
- Status last verified
- Sep 2026
- First submitted
- 17 Sep 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Peer Ambassador in Gynecologic Oncology Clinical Trials
- ClinicalTrials.gov ID
- NCT07915336
- Acronym / sponsor ID
- UPCC 20826
- Conditions
- Ovarian Cancer
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Collaborators
- Johns Hopkins University
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 4 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn if peer ambassador support will increase clinical trial enrollment in patients with ovarian cancer.
Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. The patient ambassador will be a patient with history of cancer who has participated in a clinical trial and can serve as an ambassador to facilitate discussions regarding education and awareness of clinical trials.
Detailed description
Participants will participate in a peer ambassador program where a patient ambassador (mentor) will be paired with a mentee. The patient ambassador will be a patient with history of cancer who has participated in a clinical trial and can serve as an ambassador to facilitate discussions regarding education and awareness of clinical trials. This discussion will potentially assist mentees to make informed decisions about their engagement in discussing clinical trials, looking for clinical trials, and desire and acceptance of clinical trials. This will also allow ambassadors to gain information about perceived barriers regarding clinical trials.
This study will be a multi-institutional prospective cohort study conducted at Penn and Hopkins. We seek to identify approximately 10 patient ambassadors, who will be trained to lead 1:1 discussion with patient mentees. Each ambassador will be paired with up to 10 mentees. Each ambassador-mentee pairing will have 1-2 encounters (meetings) over the course of 12 months.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Peer Ambassador Encounter | Experimental | Other: Mentee encountersMentees will participate in an enrollment session, discussion session with an ambassador, close out session, and 12 month clinical care follow up during which electronic medical records will be reviewed to assess whether mentees are subsequently screened or enrolled in clinical trials. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mentee encountersMentee meetings as previously described | Other | Peer Ambassador Encounter |
Primary outcome
Attitude about enrolling in trials
Time frame: 12 months from enrollment
Participants' attitudes about enrolling in trials will be assessed through the Attitudes Toward Cancer Trials Scales (ACTS). Scores will range from 18-126. The difference between pre and post intervention scores will be assessed.
Intent to Enroll in Trials
Time frame: 12 months from enrollment
Participants' intent to enroll in trials will be assessed through a previously validated Attitudes and Intention to Enroll in Therapeutic Clinical Trials (AIET) instrument. Responses will range from yes or no.
4 secondary outcomes
Mentee knowledge regarding clinical trials before and after discussion sessions
Time frame: Within 12 weeks of completing all sessions
Feasibility of this ambassador program
Time frame: 12 months from study start
Acceptability of this ambassador program
Time frame: 12 months from study start
Proportion of mentees in this program who enrolled onto a clinical trial
Time frame: 12 months from study start
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
Related trials for Ovarian Cancer
RecruitingPhase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian Neoplasms, Fallopian Tube Neoplasms
Active, not recruitingPhase 2
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Ovarian Clear Cell Carcinoma, Gynecologic Cancer
RecruitingObservational study
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Brain Cancer, Breast Cancer
Recruiting
Distance-Based Exercise to Preserve Function and Prevent Disability
Localized Malignant Solid Neoplasm, Anal Cancer
RecruitingPhase 1
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ovarian Neoplasms, Endometrial Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mentee encounters in people with Ovarian Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Attitude about enrolling in trials (time frame: 12 months from enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.